Hematologists’ Preferences for First-line Therapy Characteristics for Multiple Myeloma in Japan: Attribute Rating and Discrete Choice Experiment

• Published in: Clinical therapeutics Vol. 40; no. 2; pp. 296 - 308.e2
• Main Authors: Bolt, Timothy, Mahlich, Jörg, Nakamura, Yusuke, Nakayama, Masahiko
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-02-2018; Elsevier Limited
• Subjects: Aversion; Cancer; Clinical decision making; Clinical medicine; Decision making; discrete choice experiment; Experiments; hematology; Japan; Multiple myeloma; oncologists; Patients; Physicians; Preferences; Quality of life; Questionnaires; Studies; treatment preferences; Working groups; Japan; discrete choice experiment; treatment preferences; hematology; multiple myeloma; oncologists; Japan
• ISSN: 0149-2918; 1879-114X
• DOI: 10.1016/j.clinthera.2017.12.012

With the progress being made in the treatment of multiple myeloma and other complex cancers, a variety of clinical research and treatment options are being pursued. This study uses a discrete choice experiment (DCE) to estimate treatment characteristic preferences of hematologists in Japan.
A 2-stage process was applied within this study. The first stage is an attribute-rating exercise in which each of the full list of 21 attributes is rated on its importance by the clinicians when selecting a first-line therapy. The top 8 rated attributes from a stepwise logistic regression model are then used to develop a DCE to estimate hematologists’ willingness to trade-off characteristics of the treatment options in their recommendation of a first-line treatment. A logit model was used to identify the attribute levels that were the strongest determinants of the physicians’ treatment preferences.
From among the potential treatment attributes presented, improved overall survival had the most significant impact on the treatment choice of participating Japanese hematologists. Improvement in the ability to promptly reduce M-protein is also a highly prioritized treatment characteristic, with hematologists willing to sacrifice just over 1 month extra overall survival for this. Additionally, the hematologists’ value improved suitability for chromosomal abnormalities with poor prognosis, suitability of the mechanism of action in initial treatment, and promptly improving calcium-renal-anemia-bone symptoms each at roughly 0.9 months extended overall survival. The reduction of adverse events is among the other significant factors in choice of treatment, though it was not found to be as strong a determinant as those mentioned.
This study reinforces the expectation that clinical research and treatment options should continue to focus on overall survival and are key priorities in multiple myeloma treatment development. However, clinicians are willing to consider and trade off other clinical factors and markers in their choice of treatment. The potential improvements presented were also found to have a greater impact on treatment choice than aversion to the potential worse outcomes presented.